Section of Hematology & Immunology
Mission Statement
Our focus is to test newly developed drugs in the immunologic and coagulation field.
We try to combine in vitro, ex vivo and in vivo trials to obtain an integrated insight into pathophysiologic processes.
Current Projects
- First in man trials including basket trials with chemokines, cytokines, antibodies, aptamers and biosimilarity trials with biologicals
- Drug trials in human LPS infusion or lung instillation model to measure pharmacodynamics of novel compounds under standardized conditions of inflammation.
- Phase I-III patient trials, to monitor immunmodulation and coagulation in various diseases including stroke.
- Target on vessels, platelets and coagulation: Platelet hyperfunction in myocardial infarction, thrombotic microangiopathies, critically ill, extracorporeal circulations (hemodialysis, cardiopulmonary bypass, extracorporeal membrane oxygenation, left ventricular assist devices)
- Development of recombinant human diamine oxidase against mast cell activation disorders and anaphylaxis
Key Publications
1. Boehm T, Reiter B, Ristl R, Petroczi K, Sperr W, Stimpfl T, Valent P, Jilma B: Massive release of the histamine-degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients. Allergy 2018, DOI: 10.1111/all.13663
2. Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B: Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin. Blood 2019 Feb 28;133(9):893-901. doi: 10.1182/blood-2018-06-856930. Epub 2018 Dec 17.
3. Schwameis M, Roppenser B, Firbas C, Gruener CS, Model N, Stich N, Roetzer A, Buchtele N, Jilma B, Eibl MM: Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blinde, adjuvant-controlled, dose escalation first-in-man trial. Lancet Infect Dis. 2016 Jun 10. pii: S1473-3099(16)30115-3
4. Peyvandi F, Sully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni W, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichs H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombozytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522.
5. Ramsauer K, Schwameis M, Firbas C, Müllner M, Putnak RJ, Thomas SJ, Desprès P, Tauber E, Jilma B, Tangy F: Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. 2015 Feb 27. pii:S1473-3099(15)70043-5
6. Hobl EL, Stimpfl T, Ebner J, Schörgenhofer C, Derhaschnig U, Sunder-Plassmann R, Jilma-Stohlawetz P, Mannharter C, Posch M, Jilma B: Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014 Feb 25;63(7):630-5 (Award by American Heart Association)
For information please contact our Section Head:
Bernd Jilma, MD
E-Mail: bernd.jilma@meduniwien.ac.at
Quick Links
Featured
